Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1G93A Transgenic Mice

Julia Post, Anja Schaffrath, Ian Gering, Sonja Hartwig, Stefan Lehr, N. Jon Shah, Karl‐Josef Langen, Dieter Willbold, Janine Kutzsche, Antje WilluweitInternational Journal of Molecular Sciences 2021 · DOI

TL;DR

This study investigates the therapeutic potential of the D-enantiomeric peptide RD2RD2 for Amyotrophic Lateral Sclerosis (ALS) using a transgenic mouse model. Oral administration of RD2RD2 significantly improved motor function, delayed disease onset, reduced neuroinflammation, and preserved neurons in these mice, suggesting it could be a promising disease-modifying treatment for ALS.

What Problem Does This Paper Address?

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive motor neuron loss, leading to muscle weakness, paralysis, and premature death. While neuroinflammation is a known hallmark and driver of ALS progression in both patients and animal models, effective treatments remain elusive. Current therapies offer only symptomatic relief with limited impact on disease duration. This paper addresses the critical need for disease-modifying treatments by exploring the therapeutic efficacy of RD2RD2, a D-enantiomeric peptide with previously demonstrated anti-inflammatory properties, in a well-established ALS mouse model (SOD1<sup>G93A</sup>). The study aims to validate its potential for oral administration and its impact on the complex pathological cascade of ALS.

Methods

The researchers employed a comprehensive approach to evaluate RD2RD2's efficacy.

  • Animal Model: Transgenic SOD1<sup>G93A</sup> mice, which mimic key features of human ALS, were used. These mice were treated orally with RD2RD2 or a placebo from an early, pre-symptomatic stage (53 days old) for nine weeks.
  • Behavioral Assessment: A battery of tests was used to monitor motor function and disease progression:
  • SHIRPA test battery: A broad screen assessing reflexes and sensorimotor functions, including a specific motor score.
  • Pole test: Evaluated motor coordination and balance by measuring the time taken to descend a pole.
  • Grip strength test: Assessed the strength of hind limb grip.
  • Splay reflex test: Measured hind limb coordination and stability.
  • Disease Onset Analysis: The onset of motor deficits was systematically monitored using established criteria.
  • Histopathology: Brain and spinal cord tissues were analyzed using immunohistochemistry to quantify:
  • Gliosis: Activation of microglia (CD11b staining) and astrocytes (GFAP staining), key indicators of neuroinflammation.
  • Neurodegeneration: Loss of mature neurons (NeuN staining) and motor neurons (ChAT staining).
  • Plasma Cytokine Analysis: A multiplex immunoassay was used to measure levels of various inflammatory cytokines in plasma, providing insights into systemic inflammation.
  • Statistical Analysis: A range of statistical methods, including two-way repeated measures ANOVA, one-way ANOVA, and Kaplan-Meier survival analysis, were employed to analyze the data.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Oral Administration is Effective: A significant finding is that RD2RD2, when administered orally, demonstrates substantial therapeutic benefits in the SOD1<sup>G93A</sup> mouse model. This is crucial for potential clinical translation, as oral administration is a preferred and less invasive route for drug delivery.
  • Early Intervention Matters: Initiating treatment with RD2RD2 at a pre-symptomatic stage significantly impacted disease progression, highlighting the importance of early intervention in neurodegenerative diseases.
  • Multi-faceted Therapeutic Action: RD2RD2 appears to act through multiple pathways, simultaneously improving motor function, reducing neuroinflammation (gliosis), and protecting neurons from degeneration. This broad action is promising for a complex disease like ALS.
  • Neuroinflammation as a Key Target: The study strongly reinforces the role of neuroinflammation in ALS pathogenesis and demonstrates that targeting this process with RD2RD2 can lead to significant clinical improvements.
  • Potential for Disease Modification: The observed delay in disease onset and deceleration of motor deficits suggest that RD2RD2 has the potential to be a disease-modifying therapy, rather than just a symptomatic treatment.

Key Results

  • Improved Motor Performance: RD2RD2-treated SOD1<sup>G93A</sup> mice showed significantly better performance in behavioral and motor coordination tests (SHIRPA, pole test, grip strength, splay reflex) compared to placebo-treated mice.
  • Delayed Disease Onset: The average disease onset in RD2RD2-treated mice was delayed by approximately 11 days compared to placebo-treated mice, with a log-rank test showing a highly significant difference (p < 0.001).
  • Reduced Neuroinflammation: Histological analysis revealed a significant reduction in microgliosis and astrogliosis (GFAP staining) in the brain stem of RD2RD2-treated mice compared to placebo-treated mice.
  • Neuron Preservation: RD2RD2 treatment led to a significant rescue of mature neurons in the brain stem and motor cortex, bringing their numbers closer to those of non-transgenic littermates.
  • Plasma Cytokine Normalization: Analysis of plasma revealed that RD2RD2 treatment normalized the levels of several inflammatory cytokines (e.g., IL-10, IL-13, CCL-2) in SOD1<sup>G93A</sup> mice, bringing them closer to levels observed in non-transgenic mice.

Limitations and Future Work

The authors acknowledge several limitations:

  • Gender Differences: The study exclusively used female mice. They note that gender differences have been described in ALS patients and mouse models, suggesting that the drug's efficacy might differ in male mice, potentially even being stronger.
  • Mouse Model Specificity: The SOD1<sup>G93A</sup> mouse model, while well-established, primarily mimics familial ALS caused by SOD1 mutations, which represent only a subset of all ALS cases. The findings may not directly translate to sporadic ALS or ALS caused by other genetic mutations.
  • Mechanism of Action: The exact molecular mechanism by which RD2RD2 exerts its therapeutic effects remains unknown. The authors suggest that while it was initially developed for anti-amyloid-beta (Aß) activity, this is unlikely to be the primary mechanism in this ALS model, as SOD1<sup>G93A</sup> mice do not produce significant amounts of aggregating Aß. They hypothesize an off-target effect on neuroinflammatory cells.

Future work should focus on elucidating the precise mechanism of action of RD2RD2 and investigating its efficacy in other ALS models and potentially in male mice. Further development and testing are warranted to explore its potential as a disease-modifying treatment for ALS.

Summary updated

Abstract

Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and plays a key role in the pathogenesis of amyotrophic lateral sclerosis (ALS). It has been implicated as driver of disease progression and is observed in ALS patients, as well as in the transgenic SOD1<sup>G93A</sup> mouse model. Here, we explore and validate the therapeutic potential of the d-enantiomeric peptide RD2RD2 upon oral administration in SOD1<sup>G93A</sup> mice. Transgenic mice were treated daily with RD2RD2 or placebo for 10 weeks and phenotype progression was followed with several behavioural tests. At the end of the study, plasma cytokine levels and glia cell markers in brain and spinal cord were analysed. Treatment resulted in a significantly increased performance in behavioural and motor coordination tests and a decelerated neurodegenerative phenotype in RD2RD2-treated SOD1<sup>G93A</sup> mice. Additionally, we observed retardation of the average disease onset. Treatment of SOD1<sup>G93A</sup> mice led to significant reduction in glial cell activation and a rescue of neurons. Analysis of plasma revealed normalisation of several cytokines in samples of RD2RD2-treated SOD1<sup>G93A</sup> mice towards the levels of non-transgenic mice. In conclusion, these findings qualify RD2RD2 to be considered for further development and testing towards a disease modifying ALS treatment.
BibTeX
@article{post2021oral,
  author = {Julia Post and Anja Schaffrath and Ian Gering and Sonja Hartwig and Stefan Lehr and N. Jon Shah and Karl‐Josef Langen and Dieter Willbold and Janine Kutzsche and Antje Willuweit},
  title = {{Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1G93A Transgenic Mice}},
  journal = {International Journal of Molecular Sciences},
  year = {2021},
  doi = {10.3390/ijms22137066},
}
Figure